Lets Make 2016 the Takeoff Year for Publishing in the Drug Repurposing Field

Posted on
After a holiday season that – hopefully! – all of you have enjoyed, it is now time to refocus on the task at hand: advancing drug development by delving into the universe of known drugs, drug candidates, and discontinued investigational compounds, to discover new therapeutic opportunities. Achieving leadership in drug repurposing and repositioning is rapidly becoming a matter of applying a bund...
More

Patent Review Days at our Offices – Part III

Posted on
In this last part of the workflow description that we started on November 24 and continued on December 14, we discuss how we evaluate and comment the international life science patent applications that we have selected and analyzed. These commentaries need to be concise – 200-250 words on average – because we pick 12-15 documents for each issue of the Pharmaceutical Patent Analyst, and of course s...
More

Patent Review Days at our Offices – Part II

Patent Review Days at our Offices – Part II
This continues what we have started to describe on November 24, when we concluded the first part of this post with, “And then the fun begins.” Well –- looking into the international patent applications of general interest (we leave the other ones aside for this time) might not always be real fun – but it is interesting almost every time. We do not select according to rigid, quasi-algorithmic crit...
More

Our Patent Reviews of General Interest are now Open Access

Our Patent Reviews of General Interest are now Open Access
Since the journal's inception in 2012, every issue of the Future Science Group's bi-monthly Pharmaceutical Patent Analyst has carried a set of patent discussions of general interest, provided by H.M. Pharma Consultancy. Effective immediately, these contributions will be freely accessible online. The latest issue (Pharm. Pat. Anal. 2015; 4(6), 423-430) contains discussions of remarkable internat...
More

Allergan to take over… Pfizer!?

Posted on
Pfizer was founded by German immigrants to the United States 166 years ago, but it is difficult to imagine a company that is more American in character and business practices. An then, on November 23, 2015 it was announced that Pfizer will combine with Allergan in a $160 bn. deal (the largest pharmaceutical transaction ever, and the second-largest one in all history), with the merged company to be...
More

Patent Review Days at our Offices – Part I

Posted on
Recently, H.M. Pharma Consultancy is getting more inquiries concerning our patent reviews: how do we do them? What do I need to do if I want to do the same? Can I join you? Do you have patent reviewer jobs open? To answer the last question first: No, we do not offer employment of this type. But yes, we would be pleased to crowdsource patent analyses. More about this in a future post. The sec...
More

New Drug Repurposing Patents Q2/2015

Thank you for your patience while we migrated this blog to our new website, and prepared new evaluations of drug repurposing patents for publication. Here is the first part of what you will see discussed in the December 2015 Special Issue of ASSAY and Drug Development Technology – a selection of the international drug repurposing patent applications that were published during the second quarter...
More

H.M. Pharma Consultancy Publishes Paper on Galantamine Repurposing

When Soviet and Japanese scientists first characterized galantamine in the 1950s, they did not intend it to become a drug for Alzheimer's disease. The early medical uses of this plant alkaloid -- a cholinesterase inhibitor, and (as was found only much later) also a nicotinic acetylcholine receptor modulator – were for paralytic conditions and re-awakening from anesthesia, among others. Re-developm...
More

“Pharmaceutical Technology” Publishes Interview

H.M. Pharma Consultancy's drug repurposing expertise continues to draw attention. See the recent interview by Pharmtech.com here. Among the high points: our Discontinued Drug and Candidate Database (DDCD) reference tool; the untapped potential of CROs in drug repurposing collaborations; and the business models that we are seeing. In other matters, Mary Ann Liebert, Inc. has re-published the final...
More

The Roller Coaster Ride of a Drug Repurposing Journal

The Roller Coaster Ride of a Drug Repurposing Journal
The Mary Ann Liebert, Inc. journal, Drug Repurposing, Rescue, and Repositioning (DRRR) seemed to have a good start with its inaugural issue. Meanwhile, the publisher has decided that this fledgling product needs "incubation" under the wing of their long-established journal, ASSAY and Drug Development Technologies where DRRR will be hosted as a semi-annual Special Issue. Now a good part of drug ...
More